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INTRODUCTION
Anemia is defined from greek word, without (an) blood (haem ) meaning “No blood” 
Anemia is a global problem. It is a direct cause of 5-25% of maternal deaths and indirect cause 
in 20-40% of maternal deaths.  A recent update of WHO publication on institutional anemia 
(1992) reports that about half of the pregnant women in the world suffer from constitutional 
anemia, which is the most common deficiency state.
Iron has for long been considered important for the body, calcined iron (Lauha bhaswa ) 
has been used in ancient Indian medicine.  Iron deficiency anemia is the commonest nutritional 
deficiency  in  pregnancy,  followed  by  folate  deficiency.    Deficiency  of  vitamin  B12  is 
relatively less common in non-industrialized countries. 
Incidence of Anemia in Women
Anemia is a problem of gigantic proportions.  Some statistics are worth considering
 Anemia, Particularly, Iron deficiency affects 2 billion people world – wide
 Affects 44-56% of pregnant women in developing countries
 Affects 18% of pregnant women in industrialized nations
 Prevalence of anemia in India is about 60% and increases to 80% during pregnancy.
 In India, out of a pregnant population of 22 million women, it affects 13 million pregnant 
women.
 In  India,  about  0.5  million  women  die  annually,  as  a  result  of  pregnancy  and  its 
complications, Anemia is the leading contributor to this appallingly high maternal mortality 
rate
 Anemia is directly responsible for 20% of maternal deaths and another 20% die due to 
indirect consequences of anemia like obstetric hemorrhage, sepsis etc.,
The  female  is  always  in  precarious  iron  balance  during  reproductive  years  in  most 
developing countries.
Most women are not able to develop adequate iron stores during the growth period. 
Thus women enter pregnancy state with depleted iron stores.
The daily iron requirement of non-pregnant women is 2 mg and in pregnant women is 4 
mg per day in first trimester, increases to 6.3mg in second half of pregnancy.
The iron demand during pregnancy is 1000mg. Even after deducing iron conserved by 
amenorrhea (240-480mg), an additional 500-600mg of iron is required in pregnancy or 4-6mg 
of absorbed iron, which can only be achieved by mobilizing iron stores in addition to maximum 
iron absorption from diet.  Daily intake of iron should be 40-60mg/day, out of which only 
8-10% of iron gets absorbed per day.  But the average Indian diet contains only 10-15mg/dl, 
out of which only 3-5% of iron is absorbed.
Thus,  the amount of iron absorbed form the diet,  together with that  mobilized from 
stores is usually insufficient to meet the demands imposed by pregnancy, hence the need for 
supplementation of iron during pregnancy.
Anemia, is defined as reduction in total circulating erythrocyte mass below the critical 
level  which  leads  to  decreased  oxygen carrying  capacity  of  blood,  which  in  turn  leads  to 
hypoxia.
According  to  WHO  TRS  series  405,  1968,  it  is  a  condition  in  which  hemoglobin 
concentration is lower than normal as a result of a deficiency of one or more essential nutrients.
According to WHO TRS series 503, 1972, for the diagnosis of anemia in pregnancy, the 
hemoglobin concentration should be less than 11gm/dl and a haematocrit of  less than 33%.
According to center of disease control in 1990, anemia is defined as hemoglobin less 
than 11g/dl in the first and third trimester and less then 10.5g/dl in second trimester.
 CLASSIFICATION
WHO Classification :
Mild Anemia - 9.1 to 11gm/dl
Moderate Anemia - 7.1 to 9gm/dl
Severe Anemia - < 7 gm/dl
Although hemoglobin of 11gm% is  taken as cutoff point  as per WHO definition, in 
developing countries and India, cutoff point is taken as 10.5gm%
According to the guidelines by WHO (1999), hemoglobin percentage is represented in 
gm/lt, instead of gm/dl.
RECENT CLASSIFICATION
According to WHO 2002
- Mild / moderate anemia – 7.0 to 10.9 gm/dl
- Severe anemia – 7gm/dl
Indian council of medical research
ICMR uses four categories of  anemia depending upon hemoglobin levels.
Category 1 - Mild - 10.0 to 10.9g/dl
Category 2 - Moderate - 7.0 to 10.0g/dl
Category 3 - Severe - <7.0g/dl
Category 4 - Very severe - < 4.0g/dl
        ( Decompensated ) 
Modern Classification – Kinetic
1. Cytometric :
a. Normocytic normochromic - Anemia of chronic disease
b. Microcytic hypochromic  - Iron deficiency anemia
c. Macrocytic normochromic  - Vit.B12 deficiency, folate deficiency 
2. Erythrokinetic :
Depends on rates of RBC production and destruction eg. hemolytic anemia, thalassemias
3. Biochemical/molecular classification
Depends  on  etiology  at  molecular  level  eg.  iron  deficiency  anemia,  megaloblastic 
anemia.
NUTRITION AND WOMEN
The nutritional requirements of women differ in different stages of life.  An individual’s 
nutritional health starts to take shape while he/she is in-utero and remains the basic template 
throughout life.  Hence to give the children a well nourished body, a mother must start when 
she is pregnant.  A healthy mother makes a healthy baby who makes a healthy adult and the 
circle goes on.
Food to be eaten in abundance : Vegetables, fruits, high fibre grains like oats, 
wheat bran, bajra, jowar.
Food to be eaten in moderation : Milk and milk products (rich in calcium), breads, 
some fruits like banana, mango, chikoo, nuts (contain minerals), sea-food.
Foods to be restricted : Red meats (lamb, beef, pork), butter, cheese, ghee, fast 
food, processed & canned foods 
Dietary components – specific dietary components do not appear to have a significant effect 
on birthweight.
Macronutrients
Calories  are  the  single  most  important  nutritional  factor  in  determining  birthweight. 
Balanced  energy/  protein  supplements  –  compared  with  no  supplementation,  energy 
supplementation during pregnancy (300-850 kcal/day with less than 25% of that energy coming 
from protein ) is associated with small increases in maternal weight gain and birthweight, and a 
greater reduction in the risk of small for gestational age (SGA) infants and stillbirths.  Women 
fed a diet low in cholesterol and saturated fat had a marked decrease in preterm deliveries. 
DHA (omega –  3 polyunsaturated  fatty  acid)  appears  to  be  essential  for  early  birth 
development  during gestation and infancy.   Some studies  have demonstrated better  mental 
growth  of  offspring  of  mothers  who had taken cod-liver  oil.   Other  studies  have  reported 
similar benefits and also improvement in visual acuity and decrease in risk of allergic disorders. 
Fish  oil  supplements  or  fish  is  recommended  to  improve  neurological,  immunological  or 
physical development in the offspring.
Micronutrients
In developing countries,  consumption of multivitamins may improve birthweight and 
infant mortality. 
Calories
Calories are the single most important nutritional factor in determining birth weight. 
The recommended intake is 340kcal/day in the second trimester and 452kcal/day in the third.
Protein
The fetal/placental unit consumes approximately 1kg of protein during pregnancy, with 
the majority of this requirement in last 6 months.  To fulfill this need the mother should ingest 
1.1g/kg/day protein, which is moderately higher than the 0.8g/kg/day recommended for non-
pregnant  adult  women.  Animal  proteins  are  considered  complete  or  high  quality  proteins 
because they contain all 9 essential amino acids that the body needs for growth and repair of 
body tissues.  Plant based foods are usually incomplete.  The deficient amino acids can be 
obtained  from  soy  products,  consumption  of  foods  with  complementary  amino  acids  and 
increased intake of dairy products.
Carbohydrates
The  RDA  for  carbohydrates  in  pregnancy  is  175g/day,  up  from  130g/day  in  non-
pregnant women.
Calcium
Fetal skeletal development requires about 30 gm of calcium during pregnancy, primarily 
in the third trimester.   This much is easily mobilized from maternal stores.   The RDA for 
calcium is 1000 mg / day in pregnant & lactating women.
Vitamins and Minerals 
Women  at  risk  for  deficiency  include  those  carrying  twins,  heavy  smokers,  strict 
vegetarians, substance abusers, women with lactose deficiency.  Content varies depending on 
product  used.   A  supplement  that  contains  :  Zinc-15mg,  Copper  -2mg,  Calcium-250mg, 
Vitamin B6-2mg, Vitamin C-50mg, Vitamin D-5mcg ( 200IU) is useful.
Folic Acid requirements are higher in pregnancy, between 400-600mcg/day, best started 
in the periconceptional period.  
AIM OF THE STUDY
 To assess the efficacy of intravenous iron sucrose when compared to oral iron in the 
treatment of anemia in pregnancy.
 To compare the overall pregnancy outcome with respect to changes in the
a. Hemoglobin level
b. Serum ferritin level
 To conclude that parenteral iron therapy restores iron stores faster and more effectively than 
oral iron
 To prove that iron sucrose therapy aids in improved fetal outcome with slightly higher 
increase in fetal weight when compared with oral iron therapy.
REVIEW OF LITERATURE
In a study by Ragip A. Al et al., 2005, established that intravenous iron sucrose is a safe 
and effective alternative to oral iron in treatment of iron deficiency anemia of pregnancy.  It 
restores blood stores more rapidly and a prompt increase in hemoglobin may be achieved.
In a study by al momen et al, they compared 52 women treated with intravenous iron 
sucrose with 59 women treated with 300mg of oral iron sulfate and found that intravenous 
therapy resulted in higher hemoglobin levels in shorter periods compared with the oral therapy 
group.  They concluded that iron sucrose is safe and effective in the treatment of iron 
deficiency anemia during pregnancy.
In a study by Bayoumeu F et al, an open study involving 50 patients with hemoglobin 
levels between 8 and 10g/dl and a ferritin value of < 50 mg/dl. The oral group received 240mg 
of  iron sulfate  per  day for  4 weeks.   Treatment  efficacy was assessed by measurement  of 
hemoglobin and reticulocytes on days 8,15,21 and 30 and at delivery and of ferritin on day 30 
and at delivery.  The baby’s birth weight and iron stores were noted.  They concluded that iron 
sucrose  appears  to  be  a  treatment  without  serious  side  effects  indicated  in  correction  of 
pregnancy anemia or iron stores depletion.
A study by Yee J et al.,  this article focuses on iron sucrose, a hematinic, used more 
widely than any other for more than five decades, chiefly in Europe and now available in North 
America.  Iron sucrose has an average molecular weight of 34 to 60 kd, and after intravenous 
(IV) administration, it distributes into a volume equal to that of plasma, with a terminal half-life 
of 5 to 6 hours.  Transferrin and ferritin levels can be measured reliably 48 hours after IV 
administration of this agent. Iron sucrose carries no “black-box” warning, and a test dose is not 
required before it is administered.  Doses of 100mg can be administered over several minutes, 
and larger doses upto 300mg can be administered within 60 minutes.  Iron sucrose has been 
associated with a markedly lower incidence of life-threatening anaphylactic reactions and may 
be administered safely to those with previously documented intolerance to iron dextran or iron 
gluconate.  Nonanaphylactic reactions, including non-life threatening hypotension, nausea and 
exanthema, also are extremely uncommon with iron sucrose.
In a study by G. Perewusnyk et al, they assessed that iron-deficiency anemia forms the 
commonest nutritional pathology in pregnant women.  The current gold standard to detect iron 
deficiency remains the serum ferritin value.  Previously there was general consensus against 
parenteral iron administration i.e.  parenteral iron was only recommended for special conditions 
such as unresponsiveness to oral iron, intolerance to oral iron, severe anemia, lack of time for 
therapy etc.  However, especially in hospital settings, clinicians regularly face these conditions 
but are still worried about reactions that were described using iron preparations such as iron-
dextrans.  A widely used and safe alternative is the iron-sucrose complex, numerous reports 
show the effectiveness and safety of the iron-sucrose complex.  Good tolerance to this  iron 
formulation is partly due to the low allergenic effect of the sucrose complex, partly due to slow 
release of elementary iron from the complex.  By using parenteral iron-sucrose in cases of 
severe iron deficiency, anemia during pregnancy is treated efficiently and safely according to 
the results, and rate of blood transfusion could be reduced considerably to below 1% of patients 
per year.
In  a  study  by  Suheyl  Asma  et  al,  this  study  aimed  to  evaluate  the  therapeutic 
effectiveness, safety, and cost of intravenous iron sucrose therapy.  The computerized database 
and medical  records  of  453 patients  diagnosed with iron  deficiency anemia,  who received 
intravenous iron sucrose  therapy for iron deficiency anemia between 2004 and 2008 were 
reviewed.  The improvement of hematologic parameters and cost of therapy were evaluated 4 
weeks after therapy.  All patients responded to intravenous iron therapy, the therapy was well-
tolerated.  Although the cost of intravenous iron sucrose therapy may seem high, a  lack of 
adherence  to  therapy  and  side  effects  including  gastrointestinal  irritation  during  oral  iron 
therapy were not experienced during intravenous therapy.
In a study by Hallak M et al, the objective of this study was to determine the safety and 
efficacy of  maternal  intravenous iron administration to  avoid blood transfusion in  patients. 
Patients with persistent iron-deficiency anemia complicating pregnancy were included in this 
study.  The total iron amount needed to regenerate iron stores was calculated according to 
hemoglobin and the patients weight.
Hemoglobin, hematocrit, mean corpuscular volume, serum iron, transferring, and ferritin 
were evaluated at the start and conclusion of therapy as well as two weeks afterward. Twenty – 
six patients were included in the study, four of them delivered during the therapy course.  The 
hemoglobin increased at the start and end of therapy, respectively and continued to rise two 
weeks  later.   All  values  increased  over  2  weeks  except  for  transferrin  value,  which  was 
decreased.  Only mild and transient side effects were occasionally reported.  They concluded 
that intravenous iron administration during pregnancy is an effective method of regenerating 
hemoglobin and iron stores.  It should be considered for patients with severe iron-deficiency 
anemia complicating pregnancy.
A study by Milman N, focuses on the occurrence, prevention and treatment of anemia 
during pregnancy.  Iron deficiency anemia is the most prevalent deficiency disorder and the 
most frequent from of anemia in pregnant women.  The diagnosis relies on hemoglobin, a full 
blood count and plasma ferritin.   Among fertile,  non-pregnant women,  approximately 40% 
have ferritin of less than or equal to 30ug/l, i.e. small or absent iron reserves and therefore an 
unfavourable iron status with respect to upcoming pregnancy.  Requirements for absorbed iron 
increase  during  pregnancy from 0.8mg/day in  the  first  trimester  to  7.5mg/day in  the  third 
trimester,  on the  average approximately 4.4mg/day and dietary measures are  inadequate  to 
reduce the frequency of iron deficiency anemia.  Treatment with intravenous iron is superior to 
oral iron with respect to the hematological response. Intravenous iron of 600-1200mg should be 
considered as first option in profound iron deficiency anemia i.e. hemoglobin of <90g/l in any 
trimester  beyond 14 weeks  gestation.   This  study concluded that  profound iron  deficiency 
anemia has serious consequences for both woman and fetus and requires prompt intervention 
with intravenous iron.
In a study by  Breymann C,  it   states  that  inadequate  understanding of  the  complex 
chemistry of parenteral iron administration was previously responsible for serious side effects, 
such as toxic and allergic reactions and even anaphylactic shock, in particular with dextran 
preparation.  However, the current type II iron complexes that release iron to the endogenous 
iron – binding proteins with a half-life of about 6 hours are not only effective but carry a 
minimal risk of allergic accident and overload.  They concluded that the departmental data 
collected over 8 years  and backed by experience in 25 countries  indicate that  iron sucrose 
complex therapy is a valid first-line option for the safe and rapid reversal of iron-deficiency 
anemia of pregnancy.
In the Cochrane review by Cuervo LG, they identified 17 randomized controlled trials 
comparing treatments for iron-deficiency anemia in pregnancy, involving 2578 women.  They 
came to the conclusion that daily oral iron treatment improves hematological indices but causes 
frequent  gastrointestinal  adverse  effects.   Parenteral  iron,  on  the  other  hand,  enhances 
hematological response, compared with oral iron but there are concerns about possible adverse 
effects.
In the study by Silverstein SB, states that although oral iron is appropriate for most iron-
deficiency anemia patients, many patients do not respond to or may be intolerant of oral iron, 
or  may experience  bleeding  of  sufficient  magnitude  to  require  higher  iron  doses  than  that 
achievable  with  oral  iron.   Intravenous  iron  therapy  is  a  useful  option  for  these  patients. 
Intravenous iron sucrose and ferric gluconate have superior safety profiles compared to high-
molecular  weight  iron  dextran.   The  food  and  drug  admiistration’s  (FDA)  approval  of 
erythropoietic  –  stimulating agents  to  treat  certain  types  of  anemia has  increased usage of 
intravenous iron for functional iron deficiency anemia. 
IRON METABOLISM
Distribution :
Normal distribution includes :
1. Hemoglobin iron
2. Storage iron
3. Myoglobin iron
4. Labile pool iron
5. Transport iron
The dispersion of iron in each compartment can be affected by concurrent disease processes 
as well as by nutritional status. 
1. Hemoglobin iron :
Constitutes over 60% of total body iron.  During pregnancy, it  is  increased by 20%, in 
association with the concomitant increase in total blood volume, hemoglobin molecule contains 
0.34% iron by weight.
2. Storage iron :
Accounts for 30% of total body iron.  This iron compartment is equally divided into
• Hemosiderin  :  found  only  in  the  cells  of  the  reticuloendothelial  system  and  contains 
approximately 25% of iron by weight.
• Ferritin : found in plasma and virtually all cells of body contains 30% of iron by weight
Ferritin has the ability to release and attach iron rapidly and therefore plays a direct role in 
iron absorption.
3. Myoglobin iron :
3% distribution is myoglobin iron
4. Labile iron pool :
A study of kinetics has identified the iron that moves from the plasma to interstitial and 
intracellular fluid as labile iron pool, constitutes 10% of iron storage.  Contains 80mg of iron.
5. Parenchymal iron :
Represents 0.2 – 0.5% of body’s storage iron, contains approximately 6mg iron by weight.
6. Transport iron :
Smallest  compartment  of  iron  storage  about  less  than  0.1%.  It  is  the  most  active 
compartment. 
ABSORPTION
Absorption  occurs  in  upper  part  of  small  intestine  (duodenum  and  jejunum).   The 
average daily diet contains 10-20mg of iron. 
Dietary iron is present either as,
• Heme is better absorbed (upto 35% ) but forms a smaller fraction of dietary iron.
• Inorganic iron (nonheme iron, 5% ) is mostly in ferric form, needs to be reduced to ferrous 
form before absorption can take place.
The iron is absorbed mainly in ferrous form (Fe ++) from elemental iron rather than the ferric 
form (Fe+++) 
Mucosal cells in the proximal small intestine mediate iron absorption.  Intestinal cells 
are born in the crypts of lieberkuhn and migrate to the tips of the villi.  The cells are sloughed 
into the intestinal lumen at the end of their 2-3 day lifespan.  Absorptive cells remain attuned to 
the body requirements for iron by incorporating proportionate quantities of body iron into the 
absorptive cells.  This iron and recently absorbed iron decrease uptake of iron from the gut 
lumen  by  satiation  of  iron-binding  proteins  with  iron,  by  stimulating  an  iron-regulatory 
element, or both.  The incorporation of iron into these cells in quantities proportional to body 
stores of iron also provides a limited method of increasing iron excretion in individuals replete 
in iron.
Dietary Pathway :
 Three pathways exist in enterocytes for update of food iron.  Most absorbed iron is 
derived from heme.  Heme is digested enzymatically free of globin and enters the enterocyte as 
a metalloporphyrin.  Within the cell, iron is released from heme by heme oxygenase to pass 
into the body as inorganic iron.  Most dietary inorganic iron is ferric iron. This can enter the 
absorptive cell via the integrin –mobilferrin pathway (IMP).
Some dietary iron is reduced in the gut lumen and enters the absorptive cell  via the 
DCT-1 (divalent cation transporter ) pathway.  The proteins of both pathways interact within 
the enterocyte with paraferritin, a large protein complex capable of ferrireduction.  Excess iron 
is stored as ferritin to protect the cell from oxidative damage.  Iron leaves the cell to enter 
plasma,  facilitated  by  ferroportin  and  hephaestin,  which  associate  with  an  apotransferrin 
receptor.  The enterocyte is informed of body requirements for iron by transporting iron from 
plasma into the cell using a holotransferrin receptor.
RECENT CONCEPTS:
The regulation of iron absorption by the intestine has crucial implications for the body, 
because humans have no physiological pathway for the excretion of iron, making control at 
entry as must.
The cells of the duodenal mucosa can sense the requirements of iron by the body as a 
whole  and  automatically  get  programmed  by  the  sensor  mechanisms  as  they  mature  into 
absorptive enterocytes.
According  to  recent  research  findings  in  this  vital  area,  the  enterocytes  lining  the 
absorptive villi close to gastroduodenal junction are responsible for all iron absorption.
The acidic PH of the gastric effluent helps dissolve ingested iron and provides a proton-
rich milieu.
This facilitates reduction of ferric iron to its ferrous form by an enzyme known as ferric 
reductase, located at the apical brush border of the enterocyte.
The ferrius form then enters the enterocyte with the help of a transporter protein known 
as DMT 1 (divalent metal transporter 1 ) which is also situated at the apical brush border.
Incidentally DMT 1 plays an important role in the transport of many divalent ions such 
as manganese, cobalt, copper, zinc, calcium etc.
Once inside the enterocyte, iron is stored as ferritin if it is not immediately needed by the 
body and this storage form will be eliminated in the faeces when the cell is shed eventually.
STORAGE OF IRON :  
Iron  is stored in liner, spleen and bore narrow.  The storage form is ferritin. 
EXCERTION OF IRON :
The total amount of daily iron loss average 0.16% epidermal cell loss and sweat amount 
to a daily loss of 0.2mg, while iron loss in urine averages 0.1mg/day.  Menstruating women 
usually lose 25 to 45 ml of blood with each period, which is a loss of 13 to 23mg of iron.
THREE INDEPENDENT CONTROLS :
The control process has three dimensions, which are independent of each other but may 
overlap from time to time.
First :
It is influenced by recent dietary iron intake.
This is called “Dietary regulator”.
With this in operation, absorptive cells are resistant to iron intake for several days after 
large dietary bolus of iron.  This was called “Mucosal block” by scientists an earlier era.
Second :
Iron absorption can be modulated considerably in response to body iron stores.
This is called “stores regulator”
In other words, this regulator senses total body stores, and not dietary intake.
Third :
An unidentified  signal  communicates  the  state  of  bone  narrow erythropoiesis  to  the 
intestine.  
This is called “erythroid regulator”.
The exact mechanism of this regulator is not known, but it is believed to be carried from the 
bone narrow to the intestinal cells. 
FOLIC ACID 
The term folic acid is derived from its widespread presence in green leafy vegetables 
( Folium – leaf )
Sources : The richest sources of folate are green leafy vegetables and fruits.
Spinach, lettuce, asparagus, broccoli and lima beans are excellent sources of folate, while the 
best fruit sources are lemons, melons and bananas.  Folic acid is absorbed primarily in proximal 
jejunum and must be  provided in  the  diet.   Before  folic  acid can be absorbed,  it  must  be 
reduced  to  its  monoglutamate  form (FH1).   Pancreatic  conjugates  within  the  intestine  are 
responsible for this metabolic process.   Once this process is complete, FH1 enters the mucosal 
cells.
Pteroyl glutamic acid (PGA) or Pteroic acid (folic acid )
Appropriate  DNA synthesis  and  amino  acid   production  requires  formyl  FH4  derivatives. 
Insufficient levels of folic acid will preclude appropriate DNA synthesis and subsequently lead 
to the manifestations noted in megaloblastic anemia.
5,6,7,8 Tetrahydro folic acid (FH 4 )
7,8 Dihydro folic acid (FH2)
Dihydroglycolate reductase catalyses
NORMAL HAEMATOLOGIC EVENTS ASSOCIATED WITH PREGNANCY
The “Plethora of pregnancy” has been recognized clinically for many centuries.
The “Plethora” results from an expanded blood volume in pregnancy
This pregnancy induced hypervolemia has several important functions :
1. To meet the demands of the enlarged uterus with its greatly hypertrophied vascular system.
2. To protect the mother, and in turn the fetus, against deleterious effects of impaired venous 
return in the supine and erect positions.
3. To  safe  guard  the  mother  against  the  adverse  effects  of  blood  loss  associated  with 
parturition.
The  increase  in  blood  volume  associated  with  pregnancy  totals  between  1lt  to  2lt, 
depending on the size of the patient and several other variables that may enhance or cancel one 
another.   The two variables that  have the greatest  effect  on blood volume changes are the 
independent variation of the plasma volume and the red cell volume.
These are not at all synchronous, and their discordance accounts for most of the apparent 
“anemia” associated with pregnancy.
• Plasma volume : increases first,  beginning half way through 1st trimester, and reaches a 
peak about the 28th to 30th week, from then on, it slowly rises until term, but the rate of rise 
is so slow that it simulates a plateau effect.  The total plasma volume expansion ranges from 
25 to 50%, the wide range resulting from individual variation among normal pregnancies.
• The red cell volume, begins to rise in pregnancy late in the first trimester and continues to 
rise throughout pregnancy, following a different curve from that of the plasma volume. The 
total increase in red cell mass during pregnancy approximates 20 to 40%.
For the individual woman, the expansion of red cell mass is less than the proportional 
expansion of plasma volume.
Because  the  increase  in  red  cell  mass  in  pregnancy  lags  behind  and  is  of  smaller 
magnitude than the expansion of  plasma volume,  pregnancy demonstrates   “  an anemia of 
dilution.”
At approximately the 30th week of pregnancy, plasma volume expansion plateau and the 
progressive decline of hemoglobin concentration stops.
During  the  last  trimester  a  slight  rise  in  the  hemoglobin  concentration  towards  the 
prepregnant level may occur.
With  delivery,  there  is  a  loss  of  some  of  expanded  blood  volume  associated  with 
pregnancy, averaging, 500ml for a normal vaginal delivery and larger amounts  if delivery is by 
cesarean section.
This  expected  and  normal  loss  associated  with  delivery  leaves  the  newly  delivered 
woman  still  relatively  hypervolemic,  which  accounts  for  the  tolerance  for  hemorrhage 
characteristic of pregnant patients.
During the puerperium, there is rapid restoration to prepregnant blood, plasma and red 
cell volume levels, which takes place as rapidly as within one week.
The most interesting of these events of volume contraction is the fate of expanded red 
cell mass, with its precious iron content. 
TABLE - I
Physiological changes in blood indices during pregnancy
Chacteristics Normal Adult 
women
32-34 weeks 
Gestation
Increased / 
Decreased
Plasma volume (ML ) 2600 3850 1250 increased
Red Cell Mass (ML) 1400 1640 (without iron 
supplementation ) 
1800 (with iron 
supplementation )
Hemoglobin (g/dl) 12-14 11-12 Decreased
Red Blood cells (106/mm3) 4-5 3.4 -5 Decreased
Packed cell volume 0.36-0.44 0.32-0.36 Decreased
Mean corpuscular volume (f1) 80-97 70-95 Decreased
Mean corpuscular hemoglobin 
(pg)
27-33 26-31 Decreased
Mean corpuscular hemoglobin 
concentration (%)
32-36 30-35 Decreased
Serum Iron (ug/dl) 60-175 60-75 Decreased
Total iron binding (ug/100ml 300-350 350-400 Increased
Percentage saturation (%) 30 15 Decreased
Requirements of iron (mg/day ) 1.5-2.0 4.0 Increased
Fig - 1
PATHOPHYSIOLOGY AND STAGES OF IRON – DEFICIENCY  ANEMIA :
If inadequate intake, reduced absorption
or chronic bleeding 
Increased requirement of Iron during pregnancy
Increased absorption from intestine
Mobilization of Iron stores
Iron Stores are depleted           stage I
                                                  [    serum ferritin ]
Serum ferritin levels fall, and transferrin saturation 
decreases 
Decreased supply of iron to erythroid precursor 
Iron – restricted erythropolesis             Stage  II
                                    [    Free erythrocyte protoporphyrin ]
Accumulation of free erythrocyte protoporphyrin
Reduced erythrocyte indices         stage III
                              [    Hemoglobin 
                                                     MCV, MCH, MCHC ]
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CAUSES OF IRON – DEFICIENCY ANEMIA
 Increased requirements
 Low intake and /or bioavailability of dietary iron 
Average cereal and legume - based diet, as consumed in most developing countries has 20 – 
22 mg of iron which is adequate for an adult.  Absorption of 10% would be needed to maintain 
iron balance.  But the bioavailability of iron from such diet is very poor (3-5%) due to presence 
of phytates, tannins, oxalates, polyphenots, calcium salts and deficiency of vitamin C.
 Infections and infestations
They contribute to iron deficiency anemia by promoting iron loss.
1. Chronic  malaria  :  P.  Falciparum malaria  is  the  chief  cause  of  severe  anemia  amongst 
endemic  areas  of  tropical  Africa.   It  leads  to  anemia  by  causing  chronic  hemolysis, 
erythropoiesis suppression and secondary folate deficiency.
2. HIV  infection  :  Upto  70%  of  patients  who  have  AIDS  are  anemic.   Aetiology  is 
multifactorial.
3. Helminthic  infestations  :  Attempts  to  control  these  infestations  are  critical  for  anemia 
prevention in areas of endemicity.
 Hookworm : N. americanus and A. duodenale causes blood loss from small gut mucosa, the 
loss being proportional to number of worms.  A moderate hook worm load can induce a 
fecal iron loss of 3.4 mg/day.
 Schistosomiasis : S.hematobium causes urinary losses by damaging urinary tract.  Mean 
iron loss in cases of heavy infestation can be 0.7mg/day.  The infection is limited to Africa 
and middle east.
 Round worm and trichuriasis : Causes gastric and intestinal ulceration and provokes blood 
loss, though of a less severe degree than that observed in the above infestations.
EFFECT OF ANEMIA ON PREGNANCY
Maternal effects :
Mild anemia : May not have any effect on pregnancy and labour excepting that she will 
have low iron stores if she ventures into second pregnancy and may become moderately to 
severely anemic.
Moderate anemia : May cause increased weakness, lack of energy, fatigability and poor 
work performance.
Severe anemia : On the other hand is associated with poor outcome.
During Pregnancy :
1. Pregnant woman after four months of pregnancy starts looking pale and is not able to cope 
with her activities.  This is because, by fourth month, iron requirement of the fetus starts 
and fetal blood is formed.
2. High susceptibility to urinary tract infection, genital tract infection and frequent colds and 
cough.
3. Swollen feet and /or generalized swelling
4. Breathlessness, development of a ‘hemic murmur’ in the heart
5. Preterm labour
6. Eventually cardiac failure.
During labour, the woman is at greater risk
1. For APH and PPH. Even normal amount of blood loss may lead to collapse and death.
2. Fetal  anoxia and distress. May even end up in still-birth.
Postpartum complications:
1. Failure of lactation
2. Puerperal sepsis
3. Subinvolution
4. In case, operative procedures are carried out, delayed wound healing.
Twenty percent of all maternal mortality is due to anemia.
The effects of anemia on the fetus are also significant:
1. Low birth weight babies
2. Birth asphyxia
3. Chronic neonatal illness “Inability to thrive”
4. Poor iron stores lead to development of anemia at age 10 months.
5. Increased perinatal infant mortality rates. 
DIAGNOSIS OF IRON DEFICIENCY ANEMIA 
 Hemoglobin estimation : is the most practical method of diagnosis as it is cost – effective 
and  can  be  easily  performed  by  a  trained  technician.   The  taliquists  method  of  HB 
estimation is easy and simple to do but is not very accurate.  The copper – sulphate method 
also has many drawbacks and is not reliable.  Sahli’s method is reliable and accurate when 
done by experts and is the most commonly used method, although cyanometh – hemoglobin 
method appears to be most accurate.  
 Peripheral blood film : is another bedside indicator for diagnosis of anemia which will also 
differentiate  between  iron  deficiency  anemia,  folate  deficiency  anemia  and  hemolytic 
anemia.  In iron deficiency anemia, there is microcytosis (small red cells), hypochromia 
(pale red cells ), anisocytosis ( varying size of cells ) and poikilocytosis (abnormal shapes of 
cells )
 CBC count : This documents the severity of the anemia.  In chronic iron deficiency anemia, 
the cellular indices show a microcytic and hypochromic erythopoiesis, i.e. the MCV, MCH, 
and MCHC have values below the normal range in iron deficiency anemia.  Normal values 
are 75-1400 cubic microns, 24-33 micro microns and 30-36%  respectively of the three 
indices and values less than lower limits, is indicative of iron deficiency anemia.  
Often  the  platelet  count  is  elevated  (>450.000/ul),  this  normalizes  following  iron 
therapy.  
The WBC count is usually within reference ranges (4500-11.000/ul)
 Other blood indices : are serum iron (normal 60-175ugm/dl), total iron binding capacity 
(TIBC, normal <300mg% ) free red cell protoporphyrin.  In iron deficiency anemia, serum 
iron is less than 60ugm/dl and TIBC is >300mg%.
 Serum  ferritin  estimation  :  gives  better  picture  of  stored  iron,  as  is  bone  marrow 
examination for iron.  Ferritin is the major storage compound of iron and serum ferritin 
reflects this stored iron.  Serum ferritin falls during second and third trimester and is falsely 
increased  in  chronic  infections,  liver  diseases  and some neoplasms.   Iron  deficiency is 
suspected, if ferritin is less than 35ugm/l and less than 12ugm/l it is diagnostic of depleted 
iron store. A normal serum ferritin can be seen in patients who are deficient in iron and 
have coexistent diseases                ( hepatitis, anemia of chronic disorders ).
 Transferrin receptor concentration : This is the best indicator till date, but unfortunately not 
yet  routinely available  in most  hospitals  in  India.   Levels  of  serum transferrin  receptor 
(TFR) are increased in iron deficiency anemia.
 Bone  marrow examination  :  by  stained  marrow preparation  to  see  iron  stores  is  most 
accurate, but not practical in all cases as it is invasive. The absence of stainable iron in a 
bone marrow aspirate that contains spicules and a simultaneous control specimen containing 
stainable  iron  permits  establishment  of  a  diagnosis  of  iron  deficiency  without  other 
laboratory tests.
Bone marrow examination is done only in cases where there is no response to iron therapy 
after 4 weeks or when Kalazar is suspected or in suspected hypoplastic or aplastic anemia. 
MANAGEMENT
Parenteral  iron therapy :
Parenteral iron is practical, safe, easy and effective way to administer iron,  Parenteral 
iron  restores  iron  stores  faster  and  more  effectively  than  oral  iron.   In  India  and  other 
developing countries, there is need to supplement iron to every pregnant woman because iron 
deficiency exists in most pregnant women.  If all pregnant woman receive parenteral iron along 
with folate therapy, it should be possible to prevent iron-deficiency anemia in pregnant women. 
This also improves overall pregnancy outcome.
Different types of parenteral iron :
Iron sucrose
Iron dextran
Iron gluconate
Iron sucrose : It is dissociated by the reticuloendothelial system into iron and sucrose.  The 
iron is transferred from the blood into  iron stores that are located in the liver and bone marrow. 
The iron binds with ferritin and then is  available for  use by the body.  It  is  more  readily 
available for erythropoiesis than iron dextran.  It is assigned to pregnancy category B by the 
FDA, it is an FDA – approved drug.
Iron gluconate : It is a stable macromolecular complex.  The iron is more readily available for 
use because the complex does not have to be degraded.
Iron dextran : It is absorbed after injection into the capillaries and the lymph system.  It is 
associated with adverse side effects, hence it is not the preferred drug of choice.
Iron Sucrose
Advantages Disadvantages
Does not require a test dose
Less gastrointestinal symptoms
No risk of anaphylaxis
Good Bioavailability
Side effects include hypotension, 
pruritus, cramps, nausea, vomiting and 
headache.
Costly
Different types of oral iron supplements :
Types Molecular iron Elemental iron
Ferrous sulphate 200 mg 60 mg
Ferrous gluconate 320 mg 36 mg
Ferrous fumarate 200 mg 67 mg
Ferrous calcium citrate 556 mg 50 mg
Ferrous succinate 100 mg 35 mg
Disadvantages of oral iron therapy :
1. Intolerance
2. Unpredictable absorption : there are many factors which can inhibit iron absorption and 
utilization like antacids, oxalates and phosphates
3. Replenishing the iron stores is difficult
4. Poor compliance 
Ferrous sulphate (FeSO4)
Advantages Disadvantages
Free government supply 20% Intolerance
Dissolves quickly GI disturbances – diarrhea, nausea, 
constipation
Oxidative damage to mucosa
- Passive absorption
- Iron intoxication 
Iron Sucrose :
It is dissociated by the reticuloendothelial system into iron and sucrose.  The iron is 
transferred from the blood into iron stores that are located in the liver and bone marrow.  The 
iron binds with ferritin and then is available for use by the body.
Conditions where iron sucrose therapy is unsuitable :
1. In patients with known hypersensitivity to iron sucrose or any of its inactive components.
2. In patients with evidence of iron overload
3. In patients with anemia due to other causes, and not due to iron-deficiency.
MATERIALS AND METHODS 
 A Comparative study of changes in hemoglobin, maternal and fetal outcome, with oral 
and intravenous iron  preparation  in  pregnant  women with anemia complicating pregnancy. 
This study was undertaken in the department of obstetrics & gynecology at PSG Institute of 
Medical Sciences & Research during the period October 2008 – October 2009.
This study was conducted to prove that iron sucrose is well – tolerated and effective in 
pregnant women, with anemia complicating pregnancy.
A total of 100 pregnant women were randomly selected, who fulfilled the inclusion and 
exclusion criteria.
Inclusion criteria :
• Primigravida and multigravida between 24 and 36 weeks of gestation.
• Pregnant women with a hemoglobin level between 6 and 9gm%
• Women with established iron deficiency anemia
• Women with no prior history of blood transfusions
• Women who are not on any therapeutic iron therapy.
Exclusion criteria :
• History of hematological disease
• Multiple pregnancy
• Intolerance to iron derivatives
• Recent administration of iron therapy
• Women with risk of pre-term labour
• Women with medical complications
These 100 pregnant women, between gestational age 24 and 36 weeks were divided into 
two groups :
Group A : Consisted of pregnant women, who were given oral iron, a total of 
300  mg  of  elemental  iron  per  day,  three  100mg  iron  tablets  per  day  was 
administered. 
Group B : Consisted of pregnant women who were given iron sucrose at the 
rate of 200mg every other day, the dose for total iron sucrose was calculated from 
the following formula :
weight x ( target hemoglobin – actual hemoglobin )  x  2.4  + 500 mg ( iron 
stores ) 
In the formula, weight represented the patient’s weight before pregnancy in kilograms, 
target hemoglobin was set at 11g/dl.
In  each  infusion,  the  maximum total  dose  administered  was  200mg iron  sucrose  in 
100ml of normal saline, slow IV  infused over 30 minutes. Monitoring was done throughout the 
infusion to observe for any side effects.
Indicators of response to iron sucrose therapy :
1. Improved look of the patient
2. Better appetite
3. General feeling of well – being
4. Hematological improvement :-
a. Rise in hemoglobin values
b. Increase in serum ferritin levels
If  there  is  no  significant  improvement  evident  clinically  and  hematologically  within  three 
weeks, then diagnostic re-evaluation is needed.
Procedure of Study :
On entry into the study, eligibility was checked according to the inclusion and exclusion 
criteria and informed consent was taken from each patient.
Visit I :
Information, regarding patient’s name, address,  age, and history of amenorrhoea was 
obtained and results of general and obstetric  examination were noted, maternal weight was 
noted.
Investigations  included  estimation  of  hemoglobin  value,  serum  ferritin  level  and 
peripheral smear examination to note the type of anemia.
Iron tablets along with folic acid were given to the oral iron group.
They were advised regarding diet and were asked to take the iron tablet between meals, 
and not take coffee or tea before and after taking tablets. They were explained about repeating 
investigations during follow-up visits, after 3 weeks and 8 weeks respectively.  
The iron sucrose group was also administered folic acid along with therapy and were 
advised to avoid oral iron during iron sucrose therapy and thereafter.  They were advised to 
report any adverse side effects immediately.
They  were  explained  about  repeating  investigations  during  follow-up  visits,  after  a 
period of 3 weeks and 8 weeks respectively.
Visit II :
After a period of 3 weeks, the pregnant women were examined clinically and maternal 
weight was noted.  Hemoglobin and serum ferritin estimation was done in both groups to note 
the improvement in values.
The  side  effects  volunteered  by  the  women  were  noted  and  they  were  advised  to 
continue tablets, in the oral iron group.  The iron sucrose group were advised to continue folic 
acid, and to avoid oral iron.
On subsequent visits, general and obstetric examination was done and maternal weight 
and adverse side effects were noted.
Visit III :
After a period of 8 weeks, hemoglobin and serum ferritin estimation was done to note 
the improvement in values.  Any adverse side effects was noted.
After delivery birth weight of the baby was noted, and the oral iron group was advised to 
continue iron  tablets for the next 3 months post – partum.
Hemoglobin estimation was done by sahli’s method, which is  most practical,  cost  – 
effective and commonly used method.
Principle :
Hemoglobin is converted to acid hematin by the addition of N/10 or 0.1 N hydrochloric 
acid and the resulting brown colour is compared with standard brown glass reference blocks.
The intensity of the brown colour depends on the amount of acid hematin, which in turn, 
depends on the amount of hemoglobin in the blood sample.  
The sahli’s hemoglobinometer consists of a 
• Standard brown glass mounted on a comparator and a graduated tube.
• A special  pipette  to  measure  out  20  cumm of  blood,  this  pipette  is  supplied  with  the 
instrument.
• The tubes commonly used now are square with graduations in percent on one side and 
grams per 100ml on the other side.
Procedure :
N/10 HCL was placed in the tube upto lower meniscus, blood was drawn upto 20mm 
mark in the pipette and transferred to the acid in the tube.  The pipette was rinsed well by 
drawing up some of the acid and blood and by shaking the tube well and wait for 10 minutes to 
allow the brown colour to develop i.e. for formation of acid hematin. Then the solution was 
diluted with distilled water, adding a few drops at a time with continuous stirring, until the 
colour matched with the glass plates in the comparator.
The matching was done against natural light.  The level of the fluid was noted at its 
lower meniscus and reading corresponding to this level on the scale was read in gms/100ml.
SAHLI’S HEMOGLOBINOMETER
Peripheral smear was done to know the type of anemia.
Procedure :
A small drop of capillary blood was placed about 1 or 2 cm from one end of a pre-
cleaned slide.
Immediately, another slide with a smooth edge was placed at an angle of 25 degrees and 
moved backwards to make contact with the drop.  
The drop of blood should spread out quickly along the line of contact of the spreader 
with the slide. The blood film was then spread by a rapid, smooth, forward movement of the 
spreader until all the blood has spread or the edge of the slide is reached.  The ideal thickness 
of the smear was such that there was some overlap of red cells throughout majority of the 
length of the smear with separation and no distortion towards the tail of the film. The air-dried 
blood smear was fixed by covering the film with acetone-free methyl alcohol for 1 minute.  
Denaturation of proteins is required to prevent hemolysis of the RBCs.  The slide was 
flooded with Leishman’s stain for 5 minutes.
Double the volume of distilled water was added and left for 10 minutes. The slide was 
washed with distilled water.  The slide was air-dried and the back of the slide was wiped clean 
and was observed under the microscope, and the type of the anemia was noted.
 
Serum ferritin is done to know the iron stores.  This method is done by the Electrochem 
Illuminescence Immunoassay.
Procedure :
10 ul of sample and a monoclonal ferritin – specific antibody form a complex. After 
addition of streptavidin – coated microparticles, the complex becomes bound to the solid phase 
via interaction of biotin and streptavidin.
The reaction mixture is aspirated into the measuring cell where the microparticles are 
magnetically  captured  onto  the  surface  of  the  electrode.  Application  of  a  voltage  to  the 
electrode then induces chemiluminescent emission which is measured by a photomultiplier.
 Results  are  determined  via  a  calibration  curve  which  is  instrument  –  specifically 
generated by 2-point calibration and a master curve provided via the reagent bar code.
The following parameters were noted :
1. Hemoglobin levels and serum ferritin values :
Visit I – Baseline
Visit II – After 3 weeks
Visit III – After 8 weeks 
2. Adverse reaction monitoring
No  direct  leading  questions  were  asked  to  elicit  side  effects.  Only  those  side  effects 
volunteered by the pregnant women, were recorded.
They were asked to report immediately if there were any unpleasant symptoms during iron 
sucrose therapy or oral iron therapy.  
This report included a detailed description of the symptoms, time of onset and duration, 
whether treatment was discontinued and corrective measures taken.
3. The birth weight of the baby at  delivery was recorded.
OBSERVATIONS 
In the present study, women who were asked to take oral iron preparation containing 
300mg of elemental iron were allocated to group A.
Women who were asked to take iron sucrose therapy were allocated to group B. 
TABLE – II
DEMOGRAPHICAL DATA
Particulars Group A
(Oral Iron )
Group B
( Iron Sucrose )
No. of patients 50 50
Mean age (yrs) ±SD Range 22.7 ±2.4
18-29
21.4 ± 2.1
18 -28
Mean gestational age 26.7 ± 4.0 27.7 ±3.3
Mean wt (kg) range 52.75 ±8.27
40-75
54.14 ±7.21
40 – 70
No. Discontinued None None
In this study, 
In group A – age of cases were ranging from 18 – 29 years with mean age of 22.7 ± 
2.4 years and mean weight was 52.75 ±8.27 kg. 
And in group B – age of cases were ranging from 18-28 years with mean age of 21.4 ±
2.1 years and mean weight was 54.14 ±7.21kg.
This was found to be statistically insignificant.
No Patients from both the groups discontinued the study.
TABLE – III
Mean Hemoglobin Percentage
Mean Hb% VISIT – I 
( Baseline )
VISIT – II
( After 3 weeks )
VISIT – III
( After 8 weeks )
Group A
(Oral Iron )
8.22 9.15 9.93
Group B 8.12 10.35 11.57
(Iron Sucrose )
This  table  shows  the  mean  hemoglobin  concentration  at  the  first  visit  i.e.  baseline 
hemoglobin and the rise in hemoglobin values in the subsequent visits.
Fig.2 : Mean hemoglobin values in patients treated with 
Oral iron & Iron sucrose
Fig -3 Change in Hemoglobin Level
The comparative changes in mean hemoglobin percentage between group A & group B 
shows a significant improvement in the iron sucrose group, with a t-value of 12.45 and p < 
0.001, which was statistically significant
TABLE – IV
Mean Serum Ferritin Percentage
Mean sr. ferritin VISIT – I VISIT – II VISIT – III
( Baseline ) ( After 3 weeks ) ( After 8 weeks )
Group A
(Oral Iron )
7.82 17.4 26.64
Group B
(Iron Sucrose )
6.86 30.62 70.64
This table shows the mean serum ferritin value at the first visit (baseline ) and the rise in the 
serum ferritin levels in the subsequent visits, after 3 weeks and again after 8 weeks.
Fig. 4 : Mean Serum Ferritin levels
Fig. 5 : Change in Serum Ferritin level
The comparative changes in the mean serum ferritin values between group A and group 
B shows a significant improvement in the iron sucrose group, with  a t-value of 11.39 and 
p<0.001, which was statistically significant.
TABLE – V
Side Effects
Side effects Group A
( Oral Iron )
Group B
(Iron Sucrose )
Nausea 2 -
Heartburn 1 -
Abdominal discomfort 1 -
Metallic taste 1 -
Nausea & abdominal discomfort - -
Nausea & heart burn - -
Nausea & metallic taste - -
Nausea & diarrhoea - -
Abdominal discomfort & heart burn 1 -
Pruitus / rashes - 1
Pain at injection site - 1
Total 6 2
This table shows the profile of side effects encountered.
The data shows that, 6 pregnant women out of 50 in group A had side effects, whereas 
only two pregnant women in group B had side effects.  
This was statistically significant.
TABLE – VI
Birth Weight
Birth weight 
(kg)
Group A
(Oral Iron )
Group B
( Iron Sucrose )
< 2.5 5 None
2.5 -3 38 23
3 – 3.5 7 22
> 3.5 - 5
Total 50 50
This table shows a comparison of the baby weight at birth between the two groups.  The 
data reveals that the birth weight in group B was comparatively higher than the  birth weight in 
group A.  Significant number of babies in group B, had birth weight above the average of 
Indian babies.
DISCUSSION
This study was conducted in PSG Institute of Medical Sciences & Research, during the 
period October 2008 to October 2009.
The study was conducted to compare the efficacy of iron sucrose with oral iron in the 
treatment of pregnant women with iron deficiency anemia.  
The study was done to compare changes in hemoglobin values and serum ferritin levels, 
with oral iron and iron sucrose respectively.
The study was done to prove that iron sucrose is well-tolerated and more effective in 
restoring iron stores in pregnant women with anemia.
Total number of pregnant women included in the study were 100, between gestational 
age of  24 and 36 weeks, they were divided into two groups, group –A receiving 300mg of 
elemental iron daily and group – B, receiving iron sucrose therapy.
Rise in hemoglobin value and serum ferritin levels were checked, at entry into the study, 
after a period of 3 weeks and again after a period of 8 weeks, to note the improvement in the 
respective values.  Majority of the pregnant women with hemoglobin values in the range of 
6-9g/dl were in the gestational age of 28-32 weeks and hence had about 8 weeks time for the 
improvement in hemoglobin levels.  Among the women who delivered before the second round 
of investigations could be repeated i.e. after 8 weeks, in these patients, the hemoglobin and 
serum ferritin values were measured just prior to delivery.  
Finally at delivery, the birth weight of the baby was noted.
None of the 100 pregnant women in the study discontinued, making a total of 50 patients 
in group A and 50 patients in group B. 
Patients in both the groups were administered folic acid along with the iron preparations.
Hemoglobin concentration :
The mean hemoglobin percentage of both groups was taken, and there was a significant 
increase in the iron sucrose group with a p-value <0.001, which was statistically significant.
Serum Ferritin values :
The mean serum ferritin value of both the groups was taken and there was a significant 
increase in the iron sucrose group with a p-value <0.001, which was statistically significant.
Birth weight :
 We observed that in the iron sucrose group, women delivered babies with a higher birth 
weight, when compared with the oral iron group.
Side effects :
Only one patient in the iron sucrose group, with side-effects (pruritus), discontinued and 
was lost to follow-up.
 Only one patient complained of pain at the injection site, in the iron sucrose group, but 
continued with the study.
The side effects in the oral group of patients was noted and corrective measures were 
taken, these patients continued with the study.
There was a notable increase in the hemoglobin and serum ferritin values at the end of 
the study, in the iron sucrose group.
Iron sucrose was found to restore iron stores faster and more effectively than oral iron.
CONCLUSION
Iron is needed in pregnancy, iron sucrose is an effective alternative to oral iron 
preparations.
The compliance of the pregnant women is higher with the iron sucrose therapy.  Iron 
sucrose therapy is more effective in achieving the optimum results – an increase in hemoglobin 
concentration and an increase in ferritin levels.
Patients who were given iron sucrose had a better hemoglobin at delivery which will 
reduce maternal morbidity.
On an average, the birth weight was slightly higher in the iron sucrose group, when 
compared with the oral iron group.
Since iron sucrose has been proved to be well-tolerated, with minimal side effects, it is a 
suitable alternative to oral iron preparations in anemia complicating pregnancy.
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